Actively Recruiting

Phase 2
Age: 18Years - 80Years
All Genders
NCT05360277

Maintenance Tislelizumab + Capecitabine to Treat Metastatic Colorectal Cancer

Led by Yanhong Deng · Updated on 2023-12-12

52

Participants Needed

1

Research Sites

223 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Surgery with integrated treatment for metastatic colorectal cancer (mCRC) has created a new clinical setting known as mCRC with no evidence of disease (NED). However, these patients have a high risk of developing persistent cancer. This study aimed to investigate the efficacy and safety of Tislelizumab combined with capecitabine as a maintenance treatment for patients with mCRC-NED.

CONDITIONS

Official Title

Maintenance Tislelizumab + Capecitabine to Treat Metastatic Colorectal Cancer

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 20 and 79 years
  • Written informed consent provided
  • Histologically or cytologically confirmed colorectal cancer
  • Surgery with integrated treatment for metastatic colorectal cancer and achieved no evidence of disease (NED) status confirmed by a tumor board
  • If peritoneal metastasis is present, cytoreduction surgery must achieve no visible residual tumor (CC0)
  • No previous chemotherapy treatment
  • Metastatic disease involves a maximum of two distant organs or regions, synchronous or metachronous
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Adequate blood and organ function
Not Eligible

You will not qualify if you...

  • Presence of any other active cancer
  • Presence of active infections requiring antibiotic treatment
  • History of active autoimmune disease needing systemic treatment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Gastrointestinal Hospital, Sun Yat-sen University

Guangzhou, Guangdong, China, 510655

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Maintenance Tislelizumab + Capecitabine to Treat Metastatic Colorectal Cancer | DecenTrialz